Damora Therapeutics, Inc. (DMRA)Healthcare | Biotechnology | Waltham, United States | NasdaqCM
28.00 USD
-0.53
(-1.858%) ⇩
(July 13, 2026, 4 p.m.
EDT)
After hours: 28.00 |
Hot Take ↕ | July 11, 2026, 6:17 a.m. EDT
The immediate outlook is neutral-to-slightly-bearish despite a recent price rebound, as the asset remains trapped in a severe multi-year structural decline. While the stock has rallied from its lows over the last two weeks, the underlying business fundamentals are catastrophic: the company is burning cash with negative free cash flow, negative operating cash flow, and a return on equity of nearly -90%. The balance sheet shows massive leverage relative to earnings, and the forward P/E is negative, indicating no path to profitability in the near term. The price history confirms this deterioration, showing a cumulative loss of nearly 97% over the past four years, with the last two years marked by double-digit percentage declines. Although analysts offer a 'strong buy' recommendation with a target price significantly above current levels, this appears to be a speculative bet on a future catalyst rather than a reflection of current operational reality. With no dividend to provide income and no sustainable earnings base, the investment case relies entirely on a successful clinical trial or partnership deal that could reverse the decades-long trend of value destruction. |
| Model | MAE |
|---|---|
| AutoETS ✓ | 0.068084 |
| AutoARIMA | 0.068123 |
| MSTL | 0.069372 |
| AutoTheta | 0.077160 |
Forecast horizon: 45 days | Selected: AutoETS
| Forecast Reliability | |
|---|---|
| Score | 25% |
| H-stat | 15.81 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.961 |
| Excess Kurtosis | -0.13 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Market Cap | 1,723,489,408 |
| Forward P/E | -13.48 |
| Beta | 1.47 |
| Previous Name | Galecto, Inc. |
| Website | https://www.damoratx.com |
| Attribute | Value |
|---|---|
| 52 Week Change | 6.3153844 |
| Address1 | Building 23 |
| Address2 | Suite 105 221 Crescent Street |
| All Time High | 449.75 |
| All Time Low | 2.01 |
| Ask | 33.89 |
| Ask Size | 2 |
| Average Analyst Rating | 1.1 - Strong Buy |
| Average Daily Volume10 Day | 1,420,920 |
| Average Daily Volume3 Month | 547,550 |
| Average Volume | 547,550 |
| Average Volume10Days | 1,420,920 |
| Beta | 1.467 |
| Bid | 20.37 |
| Bid Size | 2 |
| Book Value | 6.287 |
| City | Waltham |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 28.0 |
| Current Ratio | 22.485 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,782,777,600 |
| Day High | 28.905 |
| Day Low | 26.29 |
| Display Name | Damora Therapeutics |
| Ebitda | -64,752,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -20.432 |
| Enterprise Value | 1,323,042,432 |
| Eps Current Year | -1.755 |
| Eps Forward | -2.0775 |
| Eps Trailing Twelve Months | -2.68 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 24.3071 |
| Fifty Day Average Change | 3.6928997 |
| Fifty Day Average Change Percent | 0.15192679 |
| Fifty Two Week Change Percent | 631.53845 |
| Fifty Two Week High | 38.325 |
| Fifty Two Week High Change | -10.325001 |
| Fifty Two Week High Change Percent | -0.2694064 |
| Fifty Two Week Low | 2.45 |
| Fifty Two Week Low Change | 25.55 |
| Fifty Two Week Low Change Percent | 10.428571 |
| Fifty Two Week Range | 2.45 - 38.325 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,603,978,200,000 |
| Float Shares | 41,216,634 |
| Forward Eps | -2.0775 |
| Forward P E | -13.477737 |
| Free Cashflow | -8,693,750 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 7 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.0 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.076220006 |
| Held Percent Institutions | 0.91382 |
| Implied Shares Outstanding | 61,553,194 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,724,976,000 |
| Last Split Factor | 1:25 |
| Long Business Summary | Damora Therapeutics, Inc., a biopharmaceutical company, develops therapies for the treatment of hematologic disorders in Denmark and North America. The company's lead product includes DMR-001, a investigational monoclonal antibody therapy that targets mutations in CALR, for the treatment of essential thrombocythemia; and DMR-002 and DMR-003, both anti-mutCALR-based therapies, with the intent to ultimately address the full spectrum of mutCALR MPN patients. It also develops GB3226, a small molecule inhibitor of ENL-YEATS and FLT3 for the treatment of acute myeloid leukemia. Damora Therapeutics, Inc. was founded in 2011 and is headquartered in Waltham, Massachusetts. |
| Long Name | Damora Therapeutics, Inc. |
| Market | us_market |
| Market Cap | 1,723,489,408 |
| Market State | POSTPOST |
| Max Age | 86,400 |
| Message Board Id | finmb_154090027 |
| Most Recent Quarter | 1,774,915,200 |
| Name Change Date | 2,026-07-13 |
| Net Income To Common | -235,088,992 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 1,756,112,624 |
| Number Of Analyst Opinions | 8 |
| Open | 28.28 |
| Operating Cashflow | -24,885,000 |
| Operating Margins | 0.0 |
| Payout Ratio | 0.0 |
| Phone | 781 281 9020 |
| Post Market Change | 0.0 |
| Post Market Change Percent | 0.0 |
| Post Market Price | 28.0 |
| Post Market Time | 1,783,973,404 |
| Prev Name | Galecto, Inc. |
| Previous Close | 28.53 |
| Price Eps Current Year | -15.954416 |
| Price Hint | 2 |
| Price To Book | 4.4536343 |
| Profit Margins | 0.0 |
| Quick Ratio | 22.417 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.11111 |
| Region | US |
| Regular Market Change | -0.530001 |
| Regular Market Change Percent | -1.8577 |
| Regular Market Day High | 28.905 |
| Regular Market Day Low | 26.29 |
| Regular Market Day Range | 26.29 - 28.905 |
| Regular Market Open | 28.28 |
| Regular Market Previous Close | 28.53 |
| Regular Market Price | 28.0 |
| Regular Market Time | 1,783,972,801 |
| Regular Market Volume | 269,352 |
| Return On Assets | -0.147 |
| Return On Equity | -0.89505 |
| Sand P52 Week Change | 0.20847368 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 61,553,194 |
| Shares Percent Shares Out | 0.058000002 |
| Shares Short | 3,567,900 |
| Shares Short Previous Month Date | 1,780,012,800 |
| Shares Short Prior Month | 1,402,988 |
| Short Name | Damora Therapeutics, Inc. |
| Short Percent Of Float | 0.0677 |
| Short Ratio | 4.13 |
| Source Interval | 15 |
| State | MA |
| Symbol | DMRA |
| Target High Price | 51.0 |
| Target Low Price | 35.0 |
| Target Mean Price | 43.375 |
| Target Median Price | 45.0 |
| Total Cash | 532,899,008 |
| Total Cash Per Share | 8.658 |
| Total Debt | 0 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -2.68 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 22.0503 |
| Two Hundred Day Average Change | 5.9496994 |
| Two Hundred Day Average Change Percent | 0.26982397 |
| Type Disp | Equity |
| Volume | 269,352 |
| Website | https://www.damoratx.com |
| Zip | 2,453 |